NASDAQ:OVID Ovid Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ovid Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.15 -0.01 (-0.16 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$5.86Now: $6.15▼$6.2650-Day Range$5.39MA: $6.56▼$8.1052-Week Range$1.80Now: $6.15▼$9.40Volume465,103 shsAverage Volume1.04 million shsMarket Capitalization$351.06 millionP/E RatioN/ADividend YieldN/ABeta1.93 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Ovid Therapeutics has a forecasted upside of 127.6% from its current price of $6.15.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesOvid Therapeutics has received 323 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOvid Therapeutics has received 249 “underperform” votes. (Add your “underperform” vote.)Community SentimentOvid Therapeutics has received 56.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote “Outperform” if you believe OVID will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,570.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.29% of the stock of Ovid Therapeutics is held by insiders.Percentage Held by Institutions38.28% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to decrease in the coming year, from ($1.58) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.06 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OVID Previous Symbol CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone646-661-7661Debt Debt-to-Equity Ratio0.01 Current Ratio3.02 Quick Ratio3.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book4.21Profitability EPS (Most Recent Fiscal Year)($1.54) Net Income$-60,460,000.00 Net MarginsN/A Return on Equity-167.44% Return on Assets-133.30%Miscellaneous Employees59 Outstanding Shares57,083,000Market Cap$351.06 million Next Earnings Date11/13/2020 (Estimated) OptionableNot Optionable $6.15 -0.01 (-0.16 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive OVID News and Ratings via Email Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions How has Ovid Therapeutics' stock price been impacted by COVID-19? Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 129.5% and is now trading at $6.15. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Ovid Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ovid Therapeutics. When is Ovid Therapeutics' next earnings date? Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020. View our earnings forecast for Ovid Therapeutics. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.05. View Ovid Therapeutics' earnings history. What price target have analysts set for OVID? 8 brokerages have issued 12-month target prices for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $21.00. On average, they expect Ovid Therapeutics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 127.6% from the stock's current price. View analysts' price targets for Ovid Therapeutics. Are investors shorting Ovid Therapeutics? Ovid Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,530,000 shares, an increase of 51.0% from the August 15th total of 3,000,000 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is presently 2.8 days. Currently, 12.7% of the company's shares are short sold. View Ovid Therapeutics' Short Interest. Who are some of Ovid Therapeutics' key competitors? Some companies that are related to Ovid Therapeutics include MacroGenics (MGNX), ALX Oncology (ALXO), INDIVIOR PLC/S (INVVY), Rocket Pharmaceuticals (RCKT), Generation Bio (GBIO), Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX), Epizyme (EPZM), Zogenix (ZGNX), Trillium Therapeutics (TRIL), Arcus Biosciences (RCUS), Repare Therapeutics (RPTX), Karyopharm Therapeutics (KPTI), Rhythm Pharmaceuticals (RYTM) and NGM Biopharmaceuticals (NGM). View all competitors. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Enphase Energy (ENPH). Who are Ovid Therapeutics' key executives? Ovid Therapeutics' management team includes the following people: Dr. Jeremy Max Levin, Chairman & CEO (Age 67, Pay $821.32k)Dr. Amit Rakhit, Pres & Chief Medical Officer (Age 50, Pay $694.05k)Mr. Timothy G. Daly, Exec. VP of Fin., Treasurer & Corp. Controller (Age 49, Pay $439.45k)Dr. Matthew J. During, Founder & Chairman of Scientific Advisory Board (Age 63)Ms. Lora Pike, Sr. Director of Investor Relations & PR When did Ovid Therapeutics IPO? (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. What is Ovid Therapeutics' stock symbol? Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID." Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (4.19%), FMR LLC (3.12%), CHI Advisors LLC (0.99%), CHI Advisors LLC (0.95%), Assenagon Asset Management S.A. (0.93%) and Platinum Investment Management Ltd. (0.55%). Company insiders that own Ovid Therapeutics stock include Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View institutional ownership trends for Ovid Therapeutics. Which institutional investors are selling Ovid Therapeutics stock? OVID stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, CHI Advisors LLC, CHI Advisors LLC, Platinum Investment Management Ltd., UBS Group AG, Bank of America Corp DE, Jane Street Group LLC, and Goldman Sachs Group Inc.. View insider buying and selling activity for Ovid Therapeutics. Which institutional investors are buying Ovid Therapeutics stock? OVID stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Assenagon Asset Management S.A., Nuveen Asset Management LLC, Bank of New York Mellon Corp, California Public Employees Retirement System, Charles Schwab Investment Management Inc., Virtus ETF Advisers LLC, and New York State Common Retirement Fund. Company insiders that have bought Ovid Therapeutics stock in the last two years include Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda. View insider buying and selling activity for Ovid Therapeutics. How do I buy shares of Ovid Therapeutics? Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ovid Therapeutics' stock price today? One share of OVID stock can currently be purchased for approximately $6.15. How big of a company is Ovid Therapeutics? Ovid Therapeutics has a market capitalization of $351.06 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 59 workers across the globe. What is Ovid Therapeutics' official website? The official website for Ovid Therapeutics is www.ovidrx.com. How can I contact Ovid Therapeutics? Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
